Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of human liver cancer cell lines after RBP-KD

ABSTRACT: RNA-seq of human liver cancer cell lines after RBP-KD

PROVIDER: PRJEB40455 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR4613780_1.fastq.gz	Fastqsanger.gz
	ERR4613780_2.fastq.gz	Fastqsanger.gz
	ERR4613790_1.fastq.gz	Fastqsanger.gz
	ERR4613790_2.fastq.gz	Fastqsanger.gz
	ERR4613800_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 88

Similar Datasets

RNA-seq of human liver cancer cell lines after RBP-KD

Project description:Biological replicates of Human liver cancer cell lines HepG2 (n = 2) and Huh7 (n = 2) were treated with siRNA (KD) against CCT3, DDX39A, TOP2A, PKM, STMN1, HIST1H1C, NQO1, KPNA2, PEG10, IGF2BP1, and non-targeting (NT) control. Cells were harvested 48hrs after transfection. Total RNA was extracted and sequenced with a strand-specific paired end RNA-seq protocol.

2021-12-23 | E-MTAB-9587 | biostudies-arrayexpress

RNA-Seq of circCDYL knockdown (KD) samples in HepG2, J82, and UMUC3 cells and of GRWD1, IGF2BP1, and IGF2BP2 knockdown (KD) samples in J82 and UMUC3 cells

Project description:We profile gene expression upon circCDYL KD in HepG2 cells and in two bladder cancer cell lines J82 and UMUC3 as well as upon knockdown of the RNA binding proteins (RBP) GRWD1, IGF2BP1, and IGF2BP2 in J82 and UMUC3

2020-11-11 | GSE146726 | GEO

RNA-seq of liver tissue and liver cancer cell lines

Project description:RNA-seq of liver tissue and liver cancer cell lines

| PRJEB11781 | ENA

Sequencing of liver cancer cell lines

Project description:Liver cancer is a dreadful disease with limited therapeutic options. How to translate genomic findings into biomarkers and precision treatment is challenging. A large cell line-based platform was established, termed as Liver Cancer Model Repository. Heterogeneities in patients were faithfully recapitulated by 81 liver cancer cell lines at genomic and transcriptomic levels. This platform provides a rich resource and models to study cancer drivers and drug responses in liver cancer.

| EGAS00001002237 | EGA

RNAseq data of 81 liver cancer cell lines

Project description:A large panel of 81 liver cancer cell models, designated as LIver cancer MOdel REpository (LIMORE) was constructed. These cell lines include 31 public cell lines and 50 new cell models establishend from Chinese liver cancer patients. Whole genome sequencing (WGS), exome sequencing (WES) and RNA sequencing (RNAseq) were performed to obtain the genetic information for these cell lines. These cell lines and associated data provide new models and also a rich resource for liver cancer.

2019-06-17 | GSE97098 | GEO

Gene expression analysis of kidney primary tubular epithelial cells (PTECs), SETD2-KD PTECs, PBRM1-KD PTECs and ccRCC derived cell lines

Project description:Transcriptional profiling of human WT-PTECs, SETD2-KD PTECs, PBRM1-KD PTECs, and 10 different ccRCC derived cell lines. ccRCC derived cell lines showed distict expression signatures as compared to PTECs, some of them also present in SETD2-KD PTECs, and/or PBRM1-KD PTECs.

2017-11-01 | GSE89214 | GEO

Pol III ChIP-seq of liver cancer cell lines

Project description:Pol III ChIP-seq of liver cancer cell lines

| PRJEB11765 | ENA

Effect of zebularine on primary human liver cancer cell lines

Project description:Transcriptomic changes in human liver cancer cell lines caused by the demethylating drug zebularine. Epigenomic changes such as aberrant hypermethylation and subsequent atypical gene silencing are characteristic features of human cancer. Here, we report a comprehensive characterization of epigenomic modulation caused by zebularine, an effective DNA methylation inhibitor, in human liver cancer. Using transcriptomic and epigenomic profiling, we identified a zebularine signature that classified liver cancer cell lines into two major subtypes with different drug-responses. In drug-sensitive cell lines, zebularine caused inhibition of proliferation coupled with increased apoptosis, whereas drug-resistant cell lines were associated with upregulation of oncogenic networks (e.g. E2F1, MYC, and TNF) driving liver cancer growth in vitro and in mice. Assessment of zebularine-based therapy in xenograft mouse models demonstrated potent therapeutic effects against tumors established from zebularine-sensitive but not zebularine-resistant liver cancer cells leading to increased survival and decreased pulmonary metastasis. Integration of zebularine gene expression and demethylation response signatures differentiated patients with HCC according to their survival and disease recurrence and identified a subclass of patients within the poor survivors likely to benefit from therapeutic agents that target the cancer epigenome.

2011-07-31 | GSE23991 | GEO